

OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA

M.D. GIL-SIERRA¹, M.D.P. BRICEÑO-CASADO², C. MORENO-RAMOS³, J.C. ARMARIO-HITA⁴, J.M. BORRERO-RUBIO³

¹HOSPITAL UNIVERSITARIO PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

²HOSPITAL GENERAL NUESTRA SEÑORA DEL PRADO, PHARMACY, TALAVERA DE LA REINA, SPAIN

³HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

⁴HOSPITAL UNIVERSITARIO DE PUERTO REAL, DERMATOLOGY, PUERTO REAL, SPAIN.

4. Historical research

1ISG-008

BACKGROUND

Omalizumab is a monoclonal antibody with indication for **chronic idiopathic urticaria (CIU)**. Adequate optimization of omalizumab use could provide an improvement of **efficiency** without affecting the effectiveness of this therapy.

AIM

To describe the **effectiveness** and **efficiency data** of an **optimization program** about use of omalizumab for CIU.

MATERIAL AND METHODS

Descriptive retrospective study until **June-2021**

Patients



CIU included in a program to optimize use of omalizumab

DATA: Farmatools® application and digital clinical history

- Duration of treatments
- Type of optimization (dose reduction, therapy discontinuation or both)
- Urticaria Activity Score during a 7-day period (UAS7) and costs of therapies.

Optimization

Optimization of treatment through treatment discontinuations or dose reduction was applied in **patients with DC and TR**.


Definitions for effectiveness

- No response to therapy (**NR**): UAS7>15.
- Mild disease (**MD**): UAS7=7-15.
- Adequate disease control (**DC**): UAS7≤6.
- Total response (**TR**): UAS7=0.
- Patients with **NR and presenting treatment suspension** in a certain month were assumed to be NR in the following months.

EFFECTIVENESS



Efficiency data



Savings from optimization program estimated as difference between **costs of real omalizumab doses** used in optimization program and **hypothetical costs** with usual dose (300 mg/28 days).

RESULTS

- **Patients:** 47 patients
- **Median duration of therapy with omalizumab:** 18 months
- **Optimization of omalizumab treatment:** 61.7% of patients
 - 2.1% patients only presented dose reduction
 - 23.4% discontinuation of treatment
 - 36.2% of patients had both
- **At baseline:** all patients presented NR (UAS7>15)

Total economic savings associated with optimization of treatment with omalizumab →286150€:

- 113402€ saved through dose reduction
- 172747€ saved through therapy discontinuation

EFFECTIVENESS



CONCLUSION

Our **omalizumab optimization program** for CIU provided **high efficiency**, maintaining **nearly half of patients with TR at 36 months**

CONTACT DATA

E-mail: mangilsie@yahoo.com